Developing Biomarkers for Trastuzumab-induced Cardiotoxicity (R30) (Deadline: 7/10/17)
Developing Biomarkers for Trastuzumab-induced Cardiotoxicity (R30)
Underlining problems related to cardiac dysfunction caused by antibody-based HER2 targeted therapies are very important issues related to women’s health. Innovative methods to detect potential cause(s) of cardiotoxicity are urgently needed to improve the quality of life for women with HER2-positive breast cancer. Recent data obtained from several large clinical trials have demonstrated that cardiomyopathy induced by trastuzumab is irreversible in many patients. Therefore, it is important to develop sensitive and specific testing methods and biomarkers that could detect potential cardiotoxicity induced by trastuzumab therapy to provide important information to support effective post-marketing surveillance program.
Application due July 10, 2017
AACR-Bayer Innovation and Discovery Grants (Deadline 7/13/17)
AACR-Bayer Innovation and Discovery Grants
This grants partnership will promote the key tenets of the Bayer Grants4Targets™ Initiative, providing new treatment options for cancers with high unmet medical need, encouraging innovation and translation of ideas from basic research into novel drugs, and fostering collaborations between excellent academic groups and the pharmaceutical industry. This program offers one-year grants of $25,000 to meritorious projects that examine important, and druggable*, novel targets and biomarkers.
Applications due July 13, 2017
Breast Cancer Alliance (BCA) (Deadline: 7/22/17)
Breast Cancer Alliance (BCA)
The mission of the Breast Cancer Alliance (BCA) is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure. To promote these goals, the BCA invests in innovative research, breast surgery fellowships, regional education, dignified support and screening for the uninsured and underserved.
The BCA offers the Young Investigator Grant to encourage a commitment to breast cancer research. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support.
Applications due July 22, 2017
Brian D. Novis Senior Research Award (Deadline: 8/1/17)
Brian D. Novis Senior Research Award
These awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance) as well as immunoglobulin derived amyloidosis. These awards are targeted to established investigators with a track record in myeloma or related disorders, and are designed for projects which represent a different focus, direction, or area of research from those in which they are currently funded.
In most cases, these awards will be for pilot projects to obtain sufficient funding for larger applications from NIH or similar larger funding agencies.
Applications due August 1, 2017
Radiation Science and Technology Award (Deadline: 8/1/17)
Radiation Science and Technology Award
Established in 1967, this award recognizes outstanding creative applications of radiation sciences and engineering principles. Qualification is based on meritorious scientific and engineering achievement that has important implications for radiation science and technology. The work may have been performed at any time in the past, but the findings must have been reported in peer reviewed scientific journals. In addition, the feasibility of industrial application(s) must have been established although the work need not be in widespread use at the time of the award. The nominee need not be an ANS member. Any ANS member can nominate a worthy candidate.
Nominations due August 1, 2017
Gilead Sciences Research Scholars Program in Hematology/Oncology (Deadline 9/8/17)
Gilead Sciences Research Scholars Program in Hematology/Oncology
The mission of the program is to support innovative scientific research that will advance knowledge in the field of hematology/oncology, with a focus on hematologic malignancies, and provide support for research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding in hematology/oncology.
The program is designed to support innovative translational research projects in hematology/oncology, with a focus on hematologic malignancies, that can be either based around a clinical trial with strong correlative science or laboratory investigation.
Applications due September 8, 2017
Prostate Cancer Research Program (PCRP)- Physician Research Award (Deadline: 8/10/17)
Prostate Cancer Research Program (PCRP)- Physician Research Award
The Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research.
Applications due August 10, 2017
Stand Up To Cancer (SU2C) Dream Team Translational Research Grant (Deadline: LOI by 9/5/17; Invited Full Proposal by 1/16/18)
Stand Up To Cancer (SU2C) Dream Team Translational Research Grant
The Stand Up To Cancer Dream Team Translational Research Grant will fund a translational cancer research project that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.
The ideas may focus on particular organ sites, patient populations (such as pediatrics) or on innovative methods of treatment. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care.
LOI due September 5, 2017
Invited full proposals due January 16, 2018
Clinical Investigator Career Development Grant (Deadline: 9/6/17)
Clinical Investigator Career Development Grant
The goal of the program is to prepare physician investigators to design and administer clinical research studies in lymphoma and assume primary responsibilities for clinical research, protocol writing, Institutional Review Board (IRB) submission and publication. As such, a Career Development Plan is required as part of the Grant Application. The proposed research plan should also develop the necessary knowledge and clinical research skills relevant to the investigator's career goals. The Grant is designed to provide physician investigators with support to spend 35-50 percent of their time implementing clini cal research studies in lymphoma.
**All projects must be focused on hypothesis-driven clinical research in lymphoma. The project should be developed by the Applicant and should include at least the framework of a research protocol**
Applications due September 6, 2017
CONquer canCER Now Award (Deadlines: LOI by 9/7/17; Full Proposal by 12/7/17)
CONquer canCER Now Award
By specifically targeting promising early-career scientists and providing critically needed "seed" money for innovative projects, Concern Foundation supports development of the next generation of cancer researchers and thus promotes progress in understanding cancer biology and improved approaches to cancer.
**Proposals must be hypothesis-driven and centered on cancer genetics, cancer biology, or cancer immunology**
Concern will not fund clinical trials, cancer epidemiology, or behavioral studies.
LOI due September 7, 2017
Full Proposal due December 7, 2017
Prostate Cancer Research Program (PCRP) - Cancer Clinical Consortium Award (CCA) (Deadline: 9/7/17)
Prostate Cancer Research Program (PCRP) - Cancer Clinical Consortium Award (CCA)
The mission of the FY17 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.
Applications due September 7, 2017
Prostate Cancer Research Program (PCRP)- Pathology Resource Network Award (Deadline: 9/7/17)
Prostate Cancer Research Program (PCRP)- Pathology Resource Network Award
The FY17 PCRP PCPRN Award is intended to provide infrastructure support for the development and maintenance of a prostate cancer biorepository through a collaborative network across multiple institutions that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human prostate cancer biospecimens. A major focus of the Network must be placed on the acquisition and distribution of specimens in limited supply, such as:
- Castration-resistant disease, metastatic disease, primary untreated "de novo" metastatic disease as defined by STAMPEDE or high-risk disease defined by CHAARTED, tumors of the aggressive variant phenotype
- Disproportionately affected populations, defined by ethnicity or health service access (safety net, rural, settings)
- Active surveillance populations
- Longitudinal/sequential specimens
The Network must also collect, store, and manage data derived from the distributed biospecimens, including images of the hematoxylin and eosin (H&E)-stained samples.
Applications due September 7, 2017
Prostate Cancer Research Program (PCRP)- Health Disparity Research Award (Deadline: 9/28/17)
Prostate Cancer Research Program (PCRP)- Health Disparity Research Award
The Health Disparity Research Award supports new ideas based on innovative concepts or methodologies for health disparity research with the potential to make an important contribution toward eliminating death from prostate cancer and enhancing the well-being of men impacted by the disease. Studies proposed for this award mechanism are expected to improve the understanding of and/or address factors that contribute to differences in the disease experience across populations, ultimately contributing to eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship.
Applicants for this award must explicitly state how the proposed research is related to an area of prostate cancer health disparity. The PCRP is interested in research that addresses all different aspects that contribute to health disparity in prostate cancer, including social, cultural, and/or biological contributors. Because of the emphasis on innovation, the inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required.
Any preliminary, unpublished data provided should be from the Principal Investigator (PI) or a member(s) of the research team.
Applications due September 28, 2017
Administrative Supplements for Research on Dietary Supplements (Admin Supp) (Deadline: 10/15/17)
Administrative Supplements for Research on Dietary Supplements (Admin Supp)
This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention.
Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention.
Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease.
This FOA will not support new clinical trials.
Applications due October 15, 2017
Desmoid Tumor Research Foundation (Deadline: 1/12/18)
Desmoid Tumor Research Foundation
The Desmoid Tumor Research Foundation, Inc. (“DTRF”) funds research that will advance the current scientific knowledge about desmoid tumors, moving toward the development of new treatment options and bringing us closer to our ultimate goal of a cure. DTRF is the only foundation in the world dedicated to facilitating and funding research for a cure for desmoid tumors.
We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research. Research proposals with additional sources of funding support are particularly desirable. Researchers must be willing to collaborate with other scientists and institutions with similar interests. Grantees must agree to participate as reviewers in DTRF’s future grant review cycle, as well as to exert best efforts to attend the annual fall International DTRF Desmoid Tumor Research Workshop
Applications due January 12, 2018
Fanconi Anemia Research Fund (Deadline: 2/2/18)
Fanconi Anemia Research Fund
The Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control or cure Fanconi anemia. It has a particular interest in funding interdisciplinary, translational research efforts that effectively address one or more of the following priorities:
- To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
- To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat and cure these disorders.
- To define the pathogenesis of cancers that affect persons with Fanconi anemia, and to develop strategies for early detection, prevention, treatment and cure.
- To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to develop and maintain a high quality of life.
- To support the creation of shared resources, databases and technologies for the international Fanconi anemia research community.
Applications due February 02, 2018
Adenoid Cystic Carcinoma Research Foundation (Deadline: Continuous)
Adenoid Cystic Carcinoma Research Foundation
Adenoid Cystic Carcinoma (ACC) is a rare malignancy of secretory glands, typically originating in the salivary glands though it does appear in other primary sites, including the palate, nasopharynx, tongue base, larynx, trachea, lacrimal gland, breast and vulva. There are approximately 1,200 new cases of ACC diagnosed each year in the United States, about 60% of which involve women. This cancer has a slow, and sometimes relentless, progression characterized by frequent recurrences and metastases to sites such as the lungs, liver and bones.
Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)
Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)
Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.
The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.
The sponsor considers funding of activities in many therapeutic areas including:
- Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
- Cardiovascular Disease – Venous Thromboembolism (VTE)
- Immunology – General Immunology
- Oncology – Acute Myeloid Leukemia (AML)
- Oncology – Lung Cancer
- Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
- Respiratory Disease – Interstitial Lung Disease (ILD)
Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.
UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)] (Deadline Continuous)
UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)]
The aim of the UICC ICRETT fellowships is to facilitate rapid international transfer of cancer research and clinical technology, exchange knowledge and enhance skills in basic, clinical, behavioural and epidemiological areas of cancer research cancer control and prevention and to acquire appropriate clinical management, diagnostic and therapeutic expertise for effective application and use in the home organization upon return.
- Research plan
- Cancer prevention and control (including tobacco control)
- Basic, applied and clinical cancer research Epidemiology,
- Cancer registration, public education and behavioral sciences
- Clinical training
- Surgery, radio and chemotherapy, medical oncology, multidisciplinary cancer care
- Clinical trials
- Detection and diagnosis Prevention-oriented projects are especially encouraged
Sanofi-Aventis U.S. Inc. Education Grants (Deadline continuous)
Sanofi-Aventis U.S. Inc. Education Grants
Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.
The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.
Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.
Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.
Applicant must select one of the following Therapeutic Areas:
- Genetic Diseases
- Multiple Sclerosis
- Thyroid Cancer